{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:25:22Z","timestamp":1781652322765,"version":"3.54.5"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002475","name":"Duksung Women 's University","doi-asserted-by":"crossref","award":["3000002328"],"award-info":[{"award-number":["3000002328"]}],"id":[{"id":"10.13039\/501100002475","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1111\/jcpt.12565","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T04:36:53Z","timestamp":1496723813000},"page":"607-614","source":"Crossref","is-referenced-by-count":1,"title":["Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital"],"prefix":"10.1155","volume":"42","author":[{"given":"H. Y.","family":"Sin","sequence":"first","affiliation":[{"name":"College of Pharmacy; Duksung Women's University; Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"10.1111\/jcpt.12565-BIB0001|jcpt12565-cit-0001","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-Mineral and BoneDisorder (CKD-MBD)","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0002|jcpt12565-cit-0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0897190008315905","article-title":"Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder","volume":"21","author":"How","year":"2008","journal-title":"J Pharm Pract"},{"key":"10.1111\/jcpt.12565-BIB0003|jcpt12565-cit-0003","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12565-BIB0004|jcpt12565-cit-0004","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0005|jcpt12565-cit-0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2362.2006.01665.x","article-title":"Vascular calcification and renal osteodystrophy relationship in chronic kidney disease (review)","volume":"36","author":"Moe","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/jcpt.12565-BIB0006|jcpt12565-cit-0006","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1542-4758.2007.00190.x","article-title":"Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study","volume":"11","author":"Kimata","year":"2007","journal-title":"Hemodial Int"},{"key":"10.1111\/jcpt.12565-BIB0007|jcpt12565-cit-0007","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12565-BIB0008|jcpt12565-cit-0008","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"KRN1493 study group. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12565-BIB0009|jcpt12565-cit-0009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0010|jcpt12565-cit-0010","first-page":"i24","article-title":"A new paradigm for the treatment of secondary hyperparathyroidism","volume":"1","author":"Francisco","year":"2008","journal-title":"NDT Plus"},{"key":"10.1111\/jcpt.12565-BIB0011|jcpt12565-cit-0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0012|jcpt12565-cit-0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000345172","article-title":"Vascular calcifications, arterial aging and arterial remodeling in ESRD","volume":"35","author":"London","year":"2013","journal-title":"Blood Purif"},{"key":"10.1111\/jcpt.12565-BIB0013|jcpt12565-cit-0013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/kisup.2013.90","article-title":"Calcimimetics and outcomes in CKD","volume":"3","author":"Dr\u00fceke","year":"2013","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0014|jcpt12565-cit-0014","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"EVOLVE Trial Investigators: EVOLVE Trial Investigators. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12565-BIB0015|jcpt12565-cit-0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0016|jcpt12565-cit-0016","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","article-title":"Arterial calcifications and bone histomorphometry in end-stage renal disease","volume":"15","author":"London","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12565-BIB0017|jcpt12565-cit-0017","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"EVOLVE Trial Investigators. EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12565-BIB0018|jcpt12565-cit-0018","first-page":"s1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","author":"Moe","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1111\/jcpt.12565-BIB0019|jcpt12565-cit-0019","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"CKD-MBD Guideline Working Group; Japanese society 2 for dialysis therapy. Clinical practice guideline for the management of chronic kidney disease mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"key":"10.1111\/jcpt.12565-BIB0020|jcpt12565-cit-0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0021|jcpt12565-cit-0021","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0022|jcpt12565-cit-0022","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1542-4758.2009.00377.x","article-title":"The relationship between laboratory-based Outcome measures and mortality in end-stage renal disease: a systematic review","volume":"13","author":"Desai","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1111\/jcpt.12565-BIB0023|jcpt12565-cit-0023","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1111\/jcpt.12565-BIB0024|jcpt12565-cit-0024","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1053\/j.ajkd.2015.03.036","article-title":"Association of drug effects on serum parathyroid hormone, phosphorus, and calcium levels with mortality in CKD","volume":"66","author":"Palmer","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0025|jcpt12565-cit-0025","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0026|jcpt12565-cit-0026","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1440-1797.2009.01131.x","article-title":"Review article: chronic kidney disease-mineral bone disorder: have we got the assay, right?","volume":"14","author":"Zidehsarai","year":"2009","journal-title":"Nephrology"},{"key":"10.1111\/jcpt.12565-BIB0027|jcpt12565-cit-0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2009.374","article-title":"Parathyroid hormone measurement in CKD","volume":"77","author":"Souberbielle","year":"2010","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12565-BIB0028|jcpt12565-cit-0028","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0029|jcpt12565-cit-0029","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","article-title":"The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease","volume":"17","author":"Goodman","year":"2004","journal-title":"Semin Dial"},{"key":"10.1111\/jcpt.12565-BIB0030|jcpt12565-cit-0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0031|jcpt12565-cit-0031","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfn654","article-title":"Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism","volume":"24","author":"Meola","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12565-BIB0032|jcpt12565-cit-0032","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/sdi.12357","article-title":"The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10-year evidence review","volume":"28","author":"Rodr\u00edguez","year":"2015","journal-title":"Semin Dial"},{"key":"10.1111\/jcpt.12565-BIB0033|jcpt12565-cit-0033","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/nep.12223","article-title":"Kwan BC-H, Cheng PM-S, Pang WF, Leung CB, Li PK-T. Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism","volume":"19","author":"Chow","year":"2014","journal-title":"Nephrology"},{"key":"10.1111\/jcpt.12565-BIB0034|jcpt12565-cit-0034","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12565-BIB0035|jcpt12565-cit-0035","first-page":"1","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients","volume":"12","author":"Ballinger","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jcpt.12565-BIB0036|jcpt12565-cit-0036","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/ajkd.2001.29254","article-title":"Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation","volume":"38","author":"Avram","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12565-BIB0037|jcpt12565-cit-0037","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12565-BIB0038|jcpt12565-cit-0038","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bcp.12117","article-title":"Phosphate: an old bone molecule but new cardiovascular risk factor","volume":"77","author":"Shobeiri","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12565-BIB0039|jcpt12565-cit-0039","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12565-BIB0040|jcpt12565-cit-0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12882-015-0030-8","article-title":"Parathyroid hormone changes after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study","volume":"16","author":"Peter","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1111\/jcpt.12565-BIB0041|jcpt12565-cit-0041","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00467-013-2494-8","article-title":"Remnant nephron physiology and the progression of chronic kidney disease","volume":"29","author":"Schnaper","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/jcpt.12565-BIB0042|jcpt12565-cit-0042","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pds.3845","article-title":"Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation","volume":"24","author":"Brunelli","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jcpt.12565-BIB0043|jcpt12565-cit-0043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1440-1797.2011.01530.x","article-title":"Mu\u0342oz RI and Romero MA. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis","volume":"17","author":"Montenegro","year":"2012","journal-title":"Nephrology"},{"key":"10.1111\/jcpt.12565-BIB0044|jcpt12565-cit-0044","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12565\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:39:02Z","timestamp":1692830342000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12565","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}